Answers are grounded in this paper and cite their sources.
Introduction: Glyceryl trinitrate (GTN) requires aldehyde dehydrogenase 2 (ALDH2) for bioactivation, and the ALDH2*2 variant may impair GTN responsiveness. However, clinical evidence remains inconsistent. This systematic review and meta-analysis evaluated and compared GTN responses between ALDH2*1 wild-type individuals and ALDH2*2 carriers. Methods: A systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Fifteen studies involving a total of 1,895 participants were included. Outcomes included persistent chest pain following GTN administration, changes in forearm blood flow, coronary vasodilation, and systolic blood pressure reduction. Pooled effects were calculated where appropriate. Results: The pooled analysis of two independent studies demonstrated that ALDH2*2 carriers had a significantly higher probability of persistent chest pain following GTN than ALDH2*1 wild-type individuals (OR 5.99; p<0.001). Furthermore, ALDH2*2 carriers demonstrated a diminished vasodilatory response in forearm blood flow (weighted mean difference −76.83 percentage points; p<0.001). Coronary artery vasodilation showed a similar direction of effect but was not pooled because of substantial heterogeneity. No significant difference was observed in systolic blood pressure reduction. Conclusion: ALDH2*2 carriage may be associated with reduced GTN responsiveness, with the ALDH2 polymorphism potentially more likely to affect vascular responses than systemic haemodynamic effects. However, these findings should be interpreted cautiously because of the limited number of studies and substantial heterogeneity.
No takes yet. Share an insight, caveat, or question.
Hermawan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: